- Home
- TRIP vs MNKD Comparison
TRIP vs MNKD Comparison
Compare TRIP & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRIP
- MNKD
- Stock Information
- Founded
- TRIP 2000
- MNKD 1991
- Country
- TRIP United States
- MNKD United States
- Employees
- TRIP N/A
- MNKD N/A
- Industry
- TRIP Computer Software: Programming Data Processing
- MNKD Biotechnology: Pharmaceutical Preparations
- Sector
- TRIP Technology
- MNKD Health Care
- Exchange
- TRIP Nasdaq
- MNKD Nasdaq
- Market Cap
- TRIP 2.1B
- MNKD 1.9B
- IPO Year
- TRIP 2011
- MNKD 2004
- Fundamental
- Price
- TRIP $16.03
- MNKD $6.01
- Analyst Decision
- TRIP Hold
- MNKD Buy
- Analyst Count
- TRIP 14
- MNKD 6
- Target Price
- TRIP $17.79
- MNKD $8.92
- AVG Volume (30 Days)
- TRIP 3.1M
- MNKD 2.8M
- Earning Date
- TRIP 02-12-2025
- MNKD 02-25-2025
- Dividend Yield
- TRIP N/A
- MNKD N/A
- EPS Growth
- TRIP N/A
- MNKD N/A
- EPS
- TRIP 0.26
- MNKD 0.08
- Revenue
- TRIP $1,814,000,000.00
- MNKD $267,200,000.00
- Revenue This Year
- TRIP $4.08
- MNKD $45.45
- Revenue Next Year
- TRIP $6.07
- MNKD $16.45
- P/E Ratio
- TRIP $61.75
- MNKD $75.81
- Revenue Growth
- TRIP 3.54
- MNKD 51.35
- 52 Week Low
- TRIP $12.93
- MNKD $3.17
- 52 Week High
- TRIP $28.76
- MNKD $7.63
- Technical
- Relative Strength Index (RSI)
- TRIP 66.02
- MNKD 37.75
- Support Level
- TRIP $15.10
- MNKD $5.98
- Resistance Level
- TRIP $15.57
- MNKD $6.32
- Average True Range (ATR)
- TRIP 0.55
- MNKD 0.21
- MACD
- TRIP 0.12
- MNKD -0.04
- Stochastic Oscillator
- TRIP 98.14
- MNKD 20.55
About TRIP TripAdvisor Inc.
Tripadvisor is the world's leading travel metasearch company. Its platform offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2023, 58% of revenue came from the company's core Brand Tripadvisor segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 41% of sales in 2023, and TheFork, its dining brand, represented 9% of revenue (about 8% of sales were intersegment, which are eliminated from consolidated revenue).
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.